Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MP29-02 vs Placebo and Monotherapies in Seasonal Allergic Rhinitis
NCT00651118Phase 3Completed
- Sponsor
- Meda
- Start
- Mar 2008
- Primary completion
- Jun 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of azelastine + fluticasone in seasonal allergic rhinitis (SAR) (4 arms), sponsored by Meda. Primary endpoint: Reflective Total Nasal Symptom Score at 14 days. Started Mar 2008; status: completed.
02
Drugs
azelastine + fluticasone
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT00651118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00651118.